IMPL - Impel NeuroPharma Inc (Healthcare: Biotechnology) | Projected Earnings Date: 2022-02-14 (Delayed quote data ) |
|
|
Company Profile | |
Impel NeuroPharma Inc is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Its pipeline of proprietary product candidates includes INP107 for the treatment of OFF episodes in Parkinson's Disease. |
Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |